Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Nuvation Bio executive departs after key milestones
Nuvation Bio Inc., a pharmaceutical company focused on cancer treatment with a market capitalization of $769 million, announced the departure of Dr. Jerry Wang, CEO of subsidiary AnHeart Therapeutics, ...
Business Wire11d
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded ...
Seeking Alpha18d
NUVB Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) stock price is 2.50 and Nuvation Bio Inc. (NUVB) 10-day simple moving average is 2.62. Nuvation Bio Inc. (NUVB) stock price is 2.50 and Nuvation Bio Inc. (NUVB ...
Business Insider1mon
Buy Rating on Nuvation Bio: Promising Taletrectinib Results and Strong Valuation Support $7 Target
Nuvation Bio (NUVB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
February 12, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to ...